Analysis of Pharmacoeconomic of Three Therapeutic Schemes for Mammary Cancer

OBJECTIVE To evaluate the cost-effectiveness of three chemotherapy schemes in postoperative treatment of mammary cancer, providing a basis for the further drug administration. METHODS Ninety postoperative patients with mammary cancer were divided into three groupsTAC group (docetaxel + doxorubicin + cyclophosphamide), PEC group (paclitaxel + epirubicin + cyclophosphamide), and AC group (doxorubicin + cyclophosphamide), the cost-effectiveness method in pharmacoeconomics was adopted to analyze retrospectively the three different regimens.RESULTS The overall response rate for TAC, PEC and AC were 71.87%, 73.07% and 65.62%, respectively; the costs were 11 713.49, 18 197.79 and 7 795.82 yuan, respectively, with corresponding cost-effectiveness ratios of 162.98, 249.04 and 118.80. For the chemotherapy toxicity, the PEC group was higher than those of the TAC group and AC group. CONCLUSION Scheme TAC is a better approach for postoperative treatment of soaked mammary cancer.